Overview
APVO market data
Price History
APVO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$62.63 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.76 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -222.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.50 – $48.78 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.1M · P/B 0.51 · P/S 0.47.
Company News
Aptevo Therapeutics Q2 EPS $(5.31) Beats $(6.16) EstimateBenzinga · Aug 14, 2026, 12:32 PM
8-K filing — Aptevo Therapeutics Inc. (APVO)SEC EDGAR · Aug 14, 2026, 12:10 PM
Aptevo Therapeutics Closes Warrant Inducement Transaction, Issuing New Warrants For 1.27M Shares At $4.03 Per Share; Sells 861,708 Shares In $4.03 PIPEBenzinga · Aug 13, 2026, 8:20 PM
Aptevo Therapeutics shares are trading lower. The company announced exercise of existing warrants and PIPE for $4.5 million gross proceeds.Benzinga · Aug 12, 2026, 4:35 PM
Reported Earlier: Aptevo Therapeutics Announces A New Solid Strategy Designed To Fight Cancer On Multiple Fronts; Files A Patent Application Covering A Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Designed To Strengthen Aptevo's Oncology PipelineBenzinga · Jul 27, 2026, 8:24 PM
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "4-1BB AND OX40 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS, ANTIBODIES AGAINST 4-1BB, ANTIBODIES AGAINST OX40 (FOR THE TREATMENT OF CANCER)".Benzinga · Jul 8, 2026, 8:05 PM
Andy Hill Cancer Research Endowment Awards Aptevo Therapeutics $1.5M Non-Dilutive Research Grant For APVO451.Benzinga · Jun 30, 2026, 12:20 PM
Aptevo Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS (FOR THE TREATMENT OF PROSTATE CANCER)".Benzinga · May 27, 2026, 8:20 PM
Aptevo Therapeutics Partners With Niowave To Develop Up To Three Radiopharmaceutical Oncology ProgramsBenzinga · May 27, 2026, 12:09 PM